IPP Bureau
Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio
By IPP Bureau - June 14, 2023
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Merck gets favourable verdict in patent infringement lawsuit related to Bridion
By IPP Bureau - June 14, 2023
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData
By IPP Bureau - June 13, 2023
Pfizer is likely to show GSK significant competition
InnoCan submits new patent applications for advanced pain relief technology
By IPP Bureau - June 13, 2023
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
Croma-Pharma enrolls first patient in hyaluronic acid dermal filler clinical trial in China
By IPP Bureau - June 13, 2023
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule
By IPP Bureau - June 13, 2023
UTD2 is the world's first oral epothilone microtubule inhibitor
Astellas submits new drug application for Zolbetuximab in Japan
By IPP Bureau - June 13, 2023
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
Solvay to build a multipurpose microbiology lab in Europe
By IPP Bureau - June 13, 2023
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
GSK receives USFDA file acceptance for Jemperli plus chemotherapy for the treatment of endometrial cancer
By IPP Bureau - June 12, 2023
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Novartis unveils results of survey on chronic myeloid leukemia
By IPP Bureau - June 12, 2023
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Novartis to acquire Chinook Therapeutics for US$ 3.2 bn
By IPP Bureau - June 12, 2023
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Mandaviya inaugurates CGHS Wellness Centres in Chandigarh and Panchkula
By IPP Bureau - June 12, 2023
Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023
Asence Pharma commences new plant at Ranoli, Vadodara
By IPP Bureau - June 10, 2023
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
Indoco's Baddi facility receives EUGMP certification from Health Authority of Germany
By IPP Bureau - June 10, 2023
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
